Important Lessons Learned from the COVID-19 Crisis for Clinical Trial Diversity
Sponsors and sites struggled with clinical trial diversity way before the Coronavirus pandemic began. Approximately 20% of new drugs have different effects depending on an individual’s race. This makes it important for newer treatments to be tested on a diverse patient population. Yet disabled, elderly, Hispanic, and African American patients are typically underrepresented in clinical…
